Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study

Csaki Huttner, Angela; Agnandji, Selidji Todagbe; Combescure, Christophe; Fernandes, José F; Bache, Emmanuel Bache; Kabwende, Lumeka; Ndungu, Francis Maina; Brosnahan, Jessica; Monath, Thomas P; Lemaitre, Barbara; Grillet, Stéphane; Botto, Miriam; Engler, Olivier; Portmann, Jasmine; Siegrist, Denise; Bejon, Philip; Silvera, Peter; Kremsner, Peter; Siegrist, Claire-Anne

doi:10.1016/S1473-3099(18)30165-8

Scientific article

English

Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study

ContributorsCsaki Huttner, Angela; Agnandji, Selidji Todagbe; Combescure, Christophe

; Fernandes, José F; Bache, Emmanuel Bache; Kabwende, Lumeka; Ndungu, Francis Maina; Brosnahan, Jessica; Monath, Thomas P; Lemaitre, Barbara; Grillet, Stéphane; Botto, Miriam; Engler, Olivier; Portmann, Jasmine; Siegrist, Denise; Bejon, Philip; Silvera, Peter; Kremsner, Peter; Siegrist, Claire-Anne

Published inThe Lancet Infectious Diseases, vol. 18, no. 7, p. 738-748

Publication date2018

Abstract

The recombinant vesicular stomatitis virus (rVSV) vaccine expressing the Zaire Ebola virus (ZEBOV) glycoprotein is efficacious in the weeks following single-dose injection, but duration of immunity is unknown. We aimed to assess antibody persistence at 1 and 2 years in volunteers who received single-dose rVSV-ZEBOV in three previous trials.

Affiliation entities

Research groups

Funding

Autre - Wellcome Trust

Citation (ISO format)

CSAKI HUTTNER, Angela et al. Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study. In: The Lancet Infectious Diseases, 2018, vol. 18, n° 7, p. 738–748. doi: 10.1016/S1473-3099(18)30165-8

Article (Published version)

Identifiers

PID : unige:115513
DOI : 10.1016/S1473-3099(18)30165-8
PMID : 29627147

Journal ISSN1473-3099

446views

0downloads

Creation06/12/2018 17:05:00

First validation06/12/2018 17:05:00

Update time15/03/2023 16:03:54

Status update15/03/2023 16:03:53

Last indexation31/10/2024 13:04:27

Archive ouverte UNIGE

Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study

Technical informations